Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Preparation and Characterization of Tau Oligomer Strains.

Sengupta U, Carretero-Murillo M, Kayed R.

Methods Mol Biol. 2018;1779:113-146. doi: 10.1007/978-1-4939-7816-8_9.

PMID:
29886531
2.

Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits.

Krishnan B, Kayed R, Taglialatela G.

Alzheimers Dement (N Y). 2018 Feb 14;4:89-102. doi: 10.1016/j.trci.2018.01.002. eCollection 2018.

3.

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.

Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero Murillo M, Sengupta U, Barrett A, Kayed R.

Mol Neurodegener. 2018 Mar 15;13(1):13. doi: 10.1186/s13024-018-0245-9.

4.

Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.

Bittar A, Sengupta U, Kayed R.

NPJ Vaccines. 2018 Feb 27;3:9. doi: 10.1038/s41541-018-0046-8. eCollection 2018. Review.

5.

α-Synuclein Oligomers Induce a Unique Toxic Tau Strain.

Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Gerson JE, Kayed R.

Biol Psychiatry. 2018 Jan 17. pii: S0006-3223(18)30034-9. doi: 10.1016/j.biopsych.2017.12.018. [Epub ahead of print]

6.

Azure C Targets and Modulates Toxic Tau Oligomers.

Lo Cascio F, Kayed R.

ACS Chem Neurosci. 2018 Jun 20;9(6):1317-1326. doi: 10.1021/acschemneuro.7b00501. Epub 2018 Mar 1.

PMID:
29378132
7.

Oligomeric tau-targeted immunotherapy in Tg4510 mice.

Schroeder S, Joly-Amado A, Soliman A, Sengupta U, Kayed R, Gordon MN, Morgan D.

Alzheimers Res Ther. 2017 Jun 27;9(1):46. doi: 10.1186/s13195-017-0274-6.

8.

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies.

Castillo-Carranza DL, Nilson AN, Van Skike CE, Jahrling JB, Patel K, Garach P, Gerson JE, Sengupta U, Abisambra J, Nelson P, Troncoso J, Ungvari Z, Galvan V, Kayed R.

Aging Dis. 2017 May 2;8(3):257-266. doi: 10.14336/AD.2017.0112. eCollection 2017 May.

9.

Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits.

Larson ME, Greimel SJ, Amar F, LaCroix M, Boyle G, Sherman MA, Schley H, Miel C, Schneider JA, Kayed R, Benfenati F, Lee MK, Bennett DA, Lesné SE.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4648-E4657. doi: 10.1073/pnas.1704698114. Epub 2017 May 22.

10.

Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls.

Kolarova M, Sengupta U, Bartos A, Ricny J, Kayed R.

J Alzheimers Dis. 2017;58(2):471-478. doi: 10.3233/JAD-170048.

PMID:
28453485
11.

iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases.

Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, Caraway CA, Fote GM, Madany AM, Agrawal A, Kayed R, Gylys KH, Cahalan MD, Cummings BJ, Antel JP, Mortazavi A, Carson MJ, Poon WW, Blurton-Jones M.

Neuron. 2017 Apr 19;94(2):278-293.e9. doi: 10.1016/j.neuron.2017.03.042.

12.

Tau oligomers in cerebrospinal fluid in Alzheimer's disease.

Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R.

Ann Clin Transl Neurol. 2017 Mar 1;4(4):226-235. doi: 10.1002/acn3.382. eCollection 2017 Apr.

13.

Corrigendum: Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity.

Bernini F, Malferrari D, Pignataro M, Bortolotti CA, Di Rocco G, Lancellotti L, Brigatti MF, Kayed R, Borsari M, Del Monte F, Castellini E.

Sci Rep. 2017 Jan 19;7:40897. doi: 10.1038/srep40897. No abstract available.

14.

Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo.

Gerson JE, Sengupta U, Kayed R.

Methods Mol Biol. 2017;1523:141-157.

PMID:
27975249
15.

Critical Role of the CXCL10/C-X-C Chemokine Receptor 3 Axis in Promoting Leukocyte Recruitment and Neuronal Injury during Traumatic Optic Neuropathy Induced by Optic Nerve Crush.

Ha Y, Liu H, Zhu S, Yi P, Liu W, Nathanson J, Kayed R, Loucas B, Sun J, Frishman LJ, Motamedi M, Zhang W.

Am J Pathol. 2017 Feb;187(2):352-365. doi: 10.1016/j.ajpath.2016.10.009. Epub 2016 Dec 10.

16.

Aβ Amyloid Pathology Affects the Hearts of Patients With Alzheimer's Disease: Mind the Heart.

Troncone L, Luciani M, Coggins M, Wilker EH, Ho CY, Codispoti KE, Frosch MP, Kayed R, Del Monte F.

J Am Coll Cardiol. 2016 Dec 6;68(22):2395-2407. doi: 10.1016/j.jacc.2016.08.073.

17.

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.

Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, Sengupta U, Castillo-Carranza DL, Zhang W, Gupta P, Kayed R.

J Alzheimers Dis. 2017;55(3):1083-1099.

18.

Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity.

Bernini F, Malferrari D, Pignataro M, Bortolotti CA, Di Rocco G, Lancellotti L, Brigatti MF, Kayed R, Borsari M, Del Monte F, Castellini E.

Sci Rep. 2016 Oct 24;6:35865. doi: 10.1038/srep35865. Erratum in: Sci Rep. 2017 Jan 19;7:40897.

19.

Potential mechanisms and implications for the formation of tau oligomeric strains.

Gerson JE, Mudher A, Kayed R.

Crit Rev Biochem Mol Biol. 2016 Nov/Dec;51(6):482-496. doi: 10.1080/10409238.2016.1226251. Epub 2016 Sep 21. Review.

20.

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.

Sengupta U, Nilson AN, Kayed R.

EBioMedicine. 2016 Apr;6:42-49. doi: 10.1016/j.ebiom.2016.03.035. Epub 2016 Apr 5. Review.

21.

Therapeutic Approaches Targeting Pathological Tau Aggregates.

Gerson J, Kayed R.

Curr Pharm Des. 2016;22(26):4028-39. Review.

PMID:
27189598
22.

Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.

Gerson J, Castillo-Carranza DL, Sengupta U, Bodani R, Prough DS, DeWitt DS, Hawkins BE, Kayed R.

J Neurotrauma. 2016 Nov 15;33(22):2034-2043. Epub 2016 Apr 22.

23.

Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.

Kim Y, Choi H, Lee W, Park H, Kam TI, Hong SH, Nah J, Jung S, Shin B, Lee H, Choi TY, Choo H, Kim KK, Choi SY, Kayed R, Jung YK.

Neurobiol Dis. 2016 Mar;87:19-28. doi: 10.1016/j.nbd.2015.12.006. Epub 2015 Dec 17.

PMID:
26704708
24.

Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes.

Lasagna-Reeves CA, Rousseaux MW, Guerrero-Munoz MJ, Vilanova-Velez L, Park J, See L, Jafar-Nejad P, Richman R, Orr HT, Kayed R, Zoghbi HY.

Elife. 2015 Dec 17;4. pii: e10891. doi: 10.7554/eLife.10891.

25.

Antibody against Small Aggregated Peptide Specifically Recognizes Toxic Aβ-42 Oligomers in Alzheimer's Disease.

Bodani RU, Sengupta U, Castillo-Carranza DL, Guerrero-Muñoz MJ, Gerson JE, Rudra J, Kayed R.

ACS Chem Neurosci. 2015 Dec 16;6(12):1981-9. doi: 10.1021/acschemneuro.5b00231. Epub 2015 Oct 8.

PMID:
26448453
26.

Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo.

Violet M, Chauderlier A, Delattre L, Tardivel M, Chouala MS, Sultan A, Marciniak E, Humez S, Binder L, Kayed R, Lefebvre B, Bonnefoy E, Buée L, Galas MC.

Neurobiol Dis. 2015 Oct;82:540-551. doi: 10.1016/j.nbd.2015.09.003. Epub 2015 Sep 16.

PMID:
26385829
27.

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.

Deger JM, Gerson JE, Kayed R.

Aging Cell. 2015 Oct;14(5):715-24. doi: 10.1111/acel.12359. Epub 2015 Jun 5. Review.

28.

A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1.

Lasagna-Reeves CA, Rousseaux MW, Guerrero-Muñoz MJ, Park J, Jafar-Nejad P, Richman R, Lu N, Sengupta U, Litvinchuk A, Orr HT, Kayed R, Zoghbi HY.

Elife. 2015 May 19;4. doi: 10.7554/eLife.07558.

29.

Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.

Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Hernandez C, Barrett AD, Dineley K, Kayed R.

J Neurosci. 2015 Mar 25;35(12):4857-68. doi: 10.1523/JNEUROSCI.4989-14.2015.

30.

Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.

Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, Krishnamurthy S, Farhed M, Jackson GR, Kayed R.

Biol Psychiatry. 2015 Nov 15;78(10):672-83. doi: 10.1016/j.biopsych.2014.12.019. Epub 2015 Jan 9.

PMID:
25676491
31.

Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, Ahmad Y, Jackson GR, Kayed R.

Neurobiol Dis. 2014 Nov;71:14-23. doi: 10.1016/j.nbd.2014.08.008. Epub 2014 Aug 15.

PMID:
25134727
32.

Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.

Gerson JE, Castillo-Carranza DL, Kayed R.

ACS Chem Neurosci. 2014 Sep 17;5(9):752-69. doi: 10.1021/cn500143n. Epub 2014 Aug 8. Review.

PMID:
25075869
33.

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Muñoz MJ, Troncoso J, Kayed R.

Acta Neuropathol Commun. 2014 Jun 14;2:73. doi: 10.1186/2051-5960-2-73.

34.

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes.

Lasagna-Reeves CA, Sengupta U, Castillo-Carranza D, Gerson JE, Guerrero-Munoz M, Troncoso JC, Jackson GR, Kayed R.

Acta Neuropathol Commun. 2014 May 29;2:56. doi: 10.1186/2051-5960-2-56.

35.

Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.

Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R.

J Neurosci. 2014 Mar 19;34(12):4260-72. doi: 10.1523/JNEUROSCI.3192-13.2014.

36.

Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.

Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R.

J Alzheimers Dis. 2014;40 Suppl 1:S97-S111. doi: 10.3233/JAD-132477.

PMID:
24603946
37.

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R.

Biochem Pharmacol. 2014 Apr 15;88(4):468-78. doi: 10.1016/j.bcp.2013.12.023. Epub 2014 Jan 7. Review.

PMID:
24406245
38.

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R.

Immunotargets Ther. 2013 Dec 27;3:19-28. doi: 10.2147/ITT.S40131. eCollection 2014. Review.

39.

Design of metastable β-sheet oligomers from natively unstructured peptide.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Sengupta U, White MA, Kayed R.

ACS Chem Neurosci. 2013 Dec 18;4(12):1520-3. doi: 10.1021/cn4001395. Epub 2013 Oct 14.

40.

TDP-43 Phosphorylation by casein kinase Iε promotes oligomerization and enhances toxicity in vivo.

Choksi DK, Roy B, Chatterjee S, Yusuff T, Bakhoum MF, Sengupta U, Ambegaokar S, Kayed R, Jackson GR.

Hum Mol Genet. 2014 Feb 15;23(4):1025-35. doi: 10.1093/hmg/ddt498. Epub 2013 Oct 8.

PMID:
24105464
41.

Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.

Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC 3rd, Fontaine SN, Breydo L, Zhang B, Li P, Wang L, Cotman C, Paulson HL, Muschol M, Uversky VN, Klengel T, Binder EB, Kayed R, Golde TE, Berchtold N, Dickey CA.

J Clin Invest. 2013 Oct;123(10):4158-69. doi: 10.1172/JCI69003. Epub 2013 Sep 3.

42.

Formation and propagation of tau oligomeric seeds.

Gerson JE, Kayed R.

Front Neurol. 2013 Jul 17;4:93. doi: 10.3389/fneur.2013.00093. eCollection 2013.

43.

Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies.

Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, Sengupta U, Prough DS, Jackson GR, DeWitt DS, Kayed R.

J Biol Chem. 2013 Jun 7;288(23):17042-50. doi: 10.1074/jbc.M113.472746. Epub 2013 Apr 30.

44.

Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe.

Kim HY, Sengupta U, Shao P, Guerrero-Muñoz MJ, Kayed R, Bai M.

Am J Nucl Med Mol Imaging. 2013;3(2):102-17. Epub 2013 Mar 8.

45.

Tau aggregates as immunotherapeutic targets.

Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R.

Front Biosci (Schol Ed). 2013 Jan 1;5:426-38. Review.

PMID:
23277060
46.

Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.

Lasagna-Reeves CA, Clos AL, Castillo-Carranza D, Sengupta U, Guerrero-Muñoz M, Kelly B, Wagner R, Kayed R.

Biochem Biophys Res Commun. 2013 Jan 18;430(3):963-8. doi: 10.1016/j.bbrc.2012.11.130. Epub 2012 Dec 19.

PMID:
23261448
47.

Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons.

Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, Di Paolo G, Duff KE.

J Biol Chem. 2013 Jan 18;288(3):1856-70. doi: 10.1074/jbc.M112.394528. Epub 2012 Nov 27.

48.

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau.

Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R.

Sci Rep. 2012;2:700. doi: 10.1038/srep00700. Epub 2012 Oct 3.

49.

Tau protein: function and pathology.

Rosenmann H, Blum D, Kayed R, Ittner LM.

Int J Alzheimers Dis. 2012;2012:707482. doi: 10.1155/2012/707482. Epub 2012 Aug 15. No abstract available.

50.

Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice.

Rasool S, Albay R 3rd, Martinez-Coria H, Breydo L, Wu J, Milton S, Misra S, Tran A, Pensalfini A, Laferla F, Kayed R, Glabe CG.

Mol Neurodegener. 2012 Aug 6;7:37. doi: 10.1186/1750-1326-7-37.

Supplemental Content

Support Center